Vivos Inc (RDGL)

[Timing101]

Thank DPLV...
--
Easy to break it down.. when all the DD matches...
--
So we will give the credit to the RDGL Team... Good Reading
but the best by FAR.. is the Strategic Objectives for 2019.
--
That word HUMAN .. with TESTING.. keeps coming out . Get this
team ... with the ISO Thearputics Team and patents.. and get the
BATTELLE LABS involved... major players about to make something
MAJOR happen.
---
Vivos Inc 2018 Highlights
Email Print Friendly Share
January 09, 2019 07:00 ET | Source: Vivos Inc.
Richland WA, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL)
-
The Board of Directors Reports:
In spite of being handcuffed by legacy debt financing, Vivos Inc made considerable progress in 2018. This was largely possible due to the breakthrough nature of the IsoPet® technology. Major accomplishments this past year include the following:
--
• Completed planned testing at Washington State University for the treatment of feline sarcoma. Most importantly this study confirmed the effectiveness of IsoPet for killing cancer. It further allowed us to refine techniques for safe and efficient use in future animal and human therapies.
• Utilized professional society conferences to communicate the potential of our product to veterinary and medical professionals:
o For animal therapy we had strong reception to IsoPet® at the Veterinary Cancer Society Conference setting the stage for commercializing IsoPet in the veterinary community. This is a key conference that is attended by veterinarians from across the USA and internationally.
o For human therapy we had outstanding response to our poster presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Conference in Philadelphia. We were invited to submit a paper on new innovative technology to their technical journal and also had strong interest from the president of the China Society of Nuclear Medicine.
• Intellectual property protection is a high priority:
o We updated our trademark protection of RadioGel, which is currently registered in 17 countries.
o We renegotiated our license agreement with Battelle to obtain a significant reduction in fees.
o The U.S. Patent and Trademark Office issued the Certificate of Registration for the marks RadioGelTM and IsoPet®.
• The FDA reviewed our Label and confirmed the classification of IsoPet® as a device for animal sarcoma cancer therapy. There are no remaining regulatory obstacles to commercialize IsoPet® for those cancers.
• We strengthened the Veterinary Medicine Advisory Board by adding Tariq Shah with strong commercial expertise to work with Dr. Alice Villalobos, the internationally recognized Chair of our Board.
• We established a test plan with the University of Missouri for treatment of canine soft tissue sarcoma and administered IsoPet in the first two patients. It takes about three months to assess the safety and effectiveness of the therapy.
o The first canine’s tumor was classified as CR, Complete Response. This was unprecedented compared to the standard therapies, in which the tumors tend to reoccur.
o The latest examination of the second patient, treated in late October, also looks promising with response similar to the first canine patient.
• We retained well-known analyst and consultant, George Sharp, as an Advisor. He is widely respected as a watchdog for ethical behavior in the small cap markets and has outstanding business sense.
• We strengthened our management team by bringing on Michael Pollack as our new CFO. Michael has extensive experience guiding public companies.
• Completed common stock equity financing to halt toxic selling and eliminate the secured toxic debt. This was necessary to curb the death spiral of our share price.
• Our commercialization plan is to first pilot with a local clinic and then to partner with several regional clinics across the United States:
o Signed a Memorandum of Understanding with Vista Veterinary Hospital to become the pilot clinic for commercial IsoPet® therapy. We are currently working with them on certification training and to obtain their Radioactive Material Handling license.
o Identified several interested veterinary clinics at the VCS conference that are candidates for regional clinics.
==
==
We are looking forward to another productive year in 2019. Our strategic objectives are
• Initiate the commercial sales of IsoPet.
• Secure adequate funding to expand IsoPet therapy in key regional centers.
• Begin the pre-clinical testing for human therapy.
• File for additional patent(s) to enhance our intellectual property protection.
• Continue to reduce production costs to make IsoPet more affordable for the average pet owner.
--
We realize that our loyal shareholders have gone through many emotional peaks and valleys with respect to our share price. We believe that with the elimination of our toxic debt and our progress in the development of IsoPet™ and our pending human trial testing that these trying times are at an end. We will be taking further steps to strength our company’s position while maximizing shareholder value in the near future. The Board of Directors appreciates the patience of our shareholders as we develop a legacy of advanced treatments for cancerous tumors.